leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, this inhibitor may serve as a promising therapeutic strategy for MLL leukemia by targeting CBP BrD protein.
|
31253937 |
2020 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
There is a high unmet need to identify safer and more potent therapies for MLL-rearranged (MLL-r) leukemia that can be combined with established chemotherapeutics to decrease treatment-related toxicities.
|
31325323 |
2020 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we studied the distribution and characteristics of Tregs in the LHME, investigated the effects of Treg ablation on leukemia progression, explored the mechanisms leading to Treg accumulation, and studied whether blocking Treg migration to the LHME delayed leukemia progression in MLL-AF9-induced mouse acute myeloid leukemia (AML) models using wildtype (WT) and Foxp3<sup>DTR/GFP</sup> mice.
|
31669202 |
2020 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dysregulation of MLL1 catalytic function is relevant to mixed-lineage leukemia, and targeting WDR5-MLL1 interaction could be a promising therapeutic strategy for leukemia harboring MLL1 fusion proteins.
|
30626558 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia.
|
31545325 |
2019 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
From our data we conclude that the scaffold protein 14-3-3θ enhances the aberrant activity of the chimeric transcription factor MLL-AF4 and, therefore, represents a new player in the molecular pathogenesis of t(4;11)-positive leukemia and a new promising therapeutic target.
|
31493143 |
2019 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that SOCS5 was differentially expressed in primary T-ALL and its expression levels were lowered in HOXA-deregulated leukemia harboring KMT2A gene rearrangements.
|
30974024 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we will discuss the role of MLL and its fusion partners in normal HSPCs and hematopoiesis, including the links between chromatin effectors, epigenetic landscapes, and leukemia development, and summarize current approaches to therapeutic targeting of <i>MLL</i>-r leukemias.
|
31157223 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate that the abnormal elevated expression of circAF4 regulates the cell growth via the circAF4/miR-128-3p/MLL-AF4 axis, which could contribute to leukemogenesis, suggesting that circAF4 may be a novel therapeutic target of MLL-AF4 leukemia.
|
31623653 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most importantly, IDA/MPEG-PLGA NPs significantly decreased the infiltration of leukemia blasts and improved the overall survival of MLL-AF9-induced murine leukemia compared with free IDA.
|
30666113 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, a new acute monocytic leukemia cell line with clear biological and molecular features was established and may be used in the research and development of new agents targeting KMT2A-associated leukemia.
|
31701557 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The efficiency of murine MLL-ENL-driven leukemia initiation changes with age and peaks during neonatal development.
|
31405949 |
2019 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
SETD2, an epigenetic tumor suppressor, is frequently mutated in MLL-rearranged (MLLr) leukemia and relapsed acute leukemia (AL).
|
30967619 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we address the role of MLL-FPs in the initiation of leukemia in the absence of endogenous MLL1.
|
31161857 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>LAMP5</i> was validated as being specifically and highly expressed in patients with MLL leukemia and was associated with a poor outcome.
|
30651276 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The developmental stage of the hematopoietic niche regulates lineage in <i>MLL-</i>rearranged leukemia.
|
30728174 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study provides insights into the direct regulation of the stability of MLL1 through its cleavage by taspase1, which can be harnessed for targeted therapeutic approaches for the treatment of aggressive leukemia as the result of MLL translocations.
|
30573454 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, auranofin delayed the progression of leukemia in MLL-rearranged patient-derived xenograft model and prolonged the survival of leukemic NSG mice.
|
30861284 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MLL1-AF10 fusion causes leukemia through recruiting the H3K79 histone methyltransferase DOT1L via AF10's octapeptide and leucine zipper (OM-LZ) motifs.
|
31527241 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our findings demonstrate that MN1 plays an essential role in MLL fusion leukemias and serve as a therapeutic target in MLL-rearranged acute myeloid leukemia.
|
31413090 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
DOT1L methylates histone H3K79 and is aberrantly regulated in MLL-rearranged leukemia.
|
31304633 |
2019 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JMJD1C, a member of the lysine demethylase 3 family, is aberrantly expressed in mixed lineage leukemia (MLL) gene-rearranged (MLLr) leukemias.
|
31076406 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
|
30679799 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patient-derived xenograft (PDX) models derived from patients with either MLL-r acute myeloid leukemia or MLL-r acute lymphoblastic leukemia (ALL) showed dramatic reductions of leukemia burden when treated with VTP50469.
|
31821784 |
2019 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, development of additional methods to detect specific translocation partners of KMT2A and leukemia-specific targeting drugs is important to improve further the outcomes of KMT2A-rearranged AML.
|
30869817 |
2019 |